See more : Lavras Gold Corp. (LGC.V) Income Statement Analysis – Financial Results
Complete financial analysis of Sera Prognostics, Inc. (SERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sera Prognostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Nuvama Wealth Management Limited (NUVAMA.NS) Income Statement Analysis – Financial Results
- Kaynes Technology India Limited (KAYNES.BO) Income Statement Analysis – Financial Results
- General Capital Limited (GEN.NZ) Income Statement Analysis – Financial Results
- PowerFleet, Inc. (PWFL) Income Statement Analysis – Financial Results
- Oceania Healthcare Limited (OCA.NZ) Income Statement Analysis – Financial Results
Sera Prognostics, Inc. (SERA)
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K |
| Cost of Revenue | 210.00K | 193.00K | 37.00K | 11.00K | 18.00K |
| Gross Profit | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K |
| Gross Profit Ratio | 31.37% | 27.99% | 54.88% | 56.00% | 50.00% |
| Research & Development | 15.23M | 14.24M | 11.02M | 7.78M | 9.35M |
| General & Administrative | 16.34M | 16.78M | 14.09M | 6.56M | 4.28M |
| Selling & Marketing | 8.35M | 14.70M | 10.33M | 3.65M | 2.96M |
| SG&A | 24.69M | 31.48M | 24.42M | 10.20M | 7.24M |
| Other Expenses | 0.00 | 1.53M | 1.13M | -80.00K | -17.00K |
| Operating Expenses | 39.92M | 45.73M | 35.44M | 17.99M | 16.58M |
| Cost & Expenses | 40.13M | 45.92M | 35.48M | 18.00M | 16.60M |
| Interest Income | 1.64M | 456.00K | 145.00K | 42.00K | 64.00K |
| Interest Expense | 55.00K | 61.00K | 746.00K | 1.84M | 1.97M |
| Depreciation & Amortization | 900.00K | 1.22M | 659.00K | 895.00K | 946.00K |
| EBITDA | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M |
| EBITDA Ratio | -11,531.70% | -16,464.55% | -41,784.15% | -68,456.00% | -37,786.11% |
| Operating Income | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M |
| Operating Income Ratio | -13,013.40% | -17,034.33% | -43,164.63% | -71,884.00% | -45,997.22% |
| Total Other Income/Expenses | 3.58M | 1.47M | 386.00K | -1.88M | 55.00K |
| Income Before Tax | -36.24M | -44.19M | -35.01M | -19.85M | -16.52M |
| Income Before Tax Ratio | -11,843.79% | -16,487.31% | -42,693.90% | -79,392.00% | -45,891.67% |
| Income Tax Expense | 0.00 | 61.00K | 1.22M | 1.76M | 3.92M |
| Net Income | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
| Net Income Ratio | -11,843.79% | -16,510.07% | -44,180.49% | -86,428.00% | -56,775.00% |
| EPS | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| EPS Diluted | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| Weighted Avg Shares Out | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
| Weighted Avg Shares Out (Dil) | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE
SALT LAKE CITY , Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will...
Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript
Sera Prognostics, Inc (NASDAQ:SERA ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Zhenya Lindgardt - President and Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants...
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023
SALT LAKE CITY , Oct. 25, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third...
Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Yum Brands (YUM), Inter Parfums (IPAR), TripAdvisor (TRIP) and Sera Prognostics (SERA).
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).
SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023
SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will...
Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sera Prognostics, Inc. (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
Sera Prognostics, Inc. (SERA) Q2 2023 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Peter DeNardo – Investor Relations-CapComm Partners Zhenya Lindgardt – Interim President and Chief Executive Officer Austin Aerts – Interim Chief Financial Officer...
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports